LSV Asset Management Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Posted by on May 15th, 2023

LSV Asset Management boosted its holdings in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 700.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,200 shares of the medical equipment provider’s stock after acquiring an additional 6,300 shares during the quarter. LSV Asset Management’s holdings in Hologic were worth $539,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in HOLX. Romano Brothers AND Company purchased a new stake in shares of Hologic in the 4th quarter valued at about $25,000. Whittier Trust Co. raised its holdings in shares of Hologic by 90.0% in the 4th quarter. Whittier Trust Co. now owns 380 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 180 shares in the last quarter. Salem Investment Counselors Inc. raised its holdings in shares of Hologic by 163.9% in the 2nd quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 341 shares in the last quarter. Lansing Street Advisors purchased a new stake in shares of Hologic in the 3rd quarter valued at about $44,000. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Hologic in the 4th quarter valued at about $45,000. 95.17% of the stock is currently owned by institutional investors.

Hologic Price Performance

Shares of HOLX stock opened at $82.77 on Monday. The firm has a market cap of $20.37 billion, a P/E ratio of 27.68 and a beta of 1.00. Hologic, Inc. has a fifty-two week low of $59.78 and a fifty-two week high of $87.88. The business’s 50 day moving average price is $81.71 and its 200-day moving average price is $79.04. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.69 and a current ratio of 4.41.

Hologic (NASDAQ:HOLX – Get Rating) last issued its quarterly earnings data on Monday, May 1st. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.18. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $957.53 million. Hologic had a return on equity of 19.39% and a net margin of 18.56%. The business’s quarterly revenue was down 28.5% compared to the same quarter last year. During the same period last year, the company earned $2.07 EPS. On average, equities research analysts anticipate that Hologic, Inc. will post 3.9 earnings per share for the current year.

Insider Activity at Hologic

In related news, insider Essex D. Mitchell sold 2,390 shares of Hologic stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $83.73, for a total transaction of $200,114.70. Following the sale, the insider now directly owns 7,212 shares in the company, valued at $603,860.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.66% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HOLX. Morgan Stanley raised their price objective on Hologic from $74.00 to $81.00 and gave the company an “equal weight” rating in a report on Friday, February 3rd. Mizuho raised their price objective on Hologic from $92.00 to $95.00 in a report on Tuesday, May 2nd. JPMorgan Chase & Co. raised their price objective on Hologic from $95.00 to $105.00 in a report on Tuesday, May 2nd. Citigroup raised their price objective on Hologic from $85.00 to $90.00 in a report on Tuesday, May 2nd. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Friday, April 14th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

About Hologic

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

See Also

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.